ulcerative colitis

News

AZ drops IL-23 drug for inflammatory bowel disease

AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in

News

Takeda tries again with subcutaneous Entyvio

More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerativ

News

Merck fires up a $10.8bn Prometheus takeover bid

Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion.

News

FDA won’t approve Lilly’s mirikizumab for ulcerative colitis

The FDA has issued a complete response letter to Eli Lilly, turning down its attempt to get approval for anti-IL-23p19 antibody mirikizumab as a treatment for ulcerative c

News

Open communication helps ulcerative colitis patients through COVID-19

Pfizer files blockbuster hope etrasimod for ulcerative colit...

Regulators in the US and EU have started a review of Pfizer's S1P receptor modulator etrasimod for people living with moderately-to-severely active ulcerative colitis (UC), with decisions e

News

NICE recommends Celgene's Ozanimod to treat ulcerative colit...

The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis (UC).

AZ drops IL-23 drug for inflammatory bowel disease

Takeda tries again with subcutaneous Entyvio

Merck fires up a $10.8bn Prometheus takeover bid

FDA won’t approve Lilly’s mirikizumab for ulcerative colitis

Pfizer files blockbuster hope etrasimod for ulcerative colit...

NICE recommends Celgene's Ozanimod to treat ulcerative colit...

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

ulcerative colitis

Editor's Picks